Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Triple meeting 2023 preview – firsts for Amgen and Novartis
But Repare and Black Diamond still have rebuilding to do.
